DemeRx wins FDA IND acceptance for DMX-1001 in AUD
Bottom line
DemeRx said the FDA has accepted its Investigational New Drug application for DMX-1001, an oral noribogaine candidate for alcohol use disorder, clearing the program to move forward in U.S. clinical development. The company said the IND follows a completed multiple ascending dose Phase 1 study in 55 healthy volunteers, which it reported showed safety, tolerability, and pharmacokinetics supportive of Phase 2 development. DemeRx now says it plans an alcohol interaction trial, and, if that goes as planned, a Phase 2 study could start in 2027. (biospace.com)
Why it matters: For veterinary professionals, this is human biopharma news rather than an animal health development, but it’s relevant because addiction medicine increasingly shapes the broader neuropsychiatry and translational CNS pipeline. DemeRx is positioning DMX-1001 as a neuroplastogen, a different framing from the three FDA-approved AUD drugs commonly used today, and it’s entering a treatment area where uptake of medication remains very low: NIAAA says only 2.5% of people age 12 and older with past-year AUD received medication-assisted treatment in 2024. That underscores why companies are still trying to find therapies with better durability, tolerability, and real-world adoption. (biospace.com)
What to watch: Watch for details on the alcohol interaction study, any ClinicalTrials.gov posting, and whether DemeRx can stay on track for a Phase 2 start in 2027. (biospace.com)
DemeRx has reached a regulatory milestone for DMX-1001, reporting on April 23, 2026 that the FDA accepted its IND application for the oral noribogaine candidate in alcohol use disorder. In practical terms, that gives the company the green light to continue the U.S. clinical path for a drug it describes as a novel neuroplastogen, with DemeRx saying a successful alcohol interaction trial would support a Phase 2 start in 2027. (biospace.com)
This IND acceptance builds on work DemeRx has been telegraphing for some time. In mid-2024, the company said it had started enrolling healthy volunteers into a Phase 1 oral dose study of DMX-1001, with planned dosing up to 80 mg daily across four cohorts. By January 6, 2026, DemeRx reported completion of a multiple ascending dose study in 55 healthy volunteers, saying the program showed safety, tolerability, and pharmacokinetics that supported moving ahead. (demerx.com)
The candidate itself is notable because it’s based on noribogaine, the long-acting metabolite of ibogaine. DemeRx argues that noribogaine may preserve some anti-addictive biology while avoiding ibogaine’s psychedelic effects and some of the safety and misuse concerns associated with the parent compound. In its latest announcement, the company said DMX-1001 is intended to combine neuroplasticity and polypharmacology, and in the January Phase 1 update it said cardiac assessments showed a dose-related QTc effect that was not considered clinically relevant. (demerx.com)
There’s also some scientific backstory behind the program, although it remains early-stage. Older preclinical work linked ibogaine-family compounds to reduced alcohol consumption in animal models, and mechanistic studies have explored pathways involving glial cell line-derived neurotrophic factor, or GDNF, which DemeRx now highlights in its corporate messaging around DMX-1001. That doesn’t establish clinical efficacy in people with AUD, but it helps explain why the company is trying to advance a differentiated mechanism in a field with limited innovation. (pmc.ncbi.nlm.nih.gov)
Outside commentary on this specific IND acceptance appears limited so far, which is common for an early regulatory step. The clearest reaction has come from the company itself: CEO Deborah Mash called the FDA’s action a “safe to proceed” authorization and framed it as an important milestone for both patients and the company. More broadly, federal data show why the market opportunity remains compelling. NIAAA says 28.0 million people age 12 and older had past-year AUD in 2024, yet only 697,000, or 2.5%, received medication-assisted treatment. (biospace.com)
Why it matters: For veterinary professionals, this isn’t a practice-management story, but it is a useful signal from the wider therapeutics landscape. Companion animal medicine increasingly overlaps with human CNS drug development through shared interest in behavior, anxiety, neuroplasticity, and translational pharmacology. Programs like DMX-1001 also show how unmet-need categories can attract renewed investment when standard therapies have low uptake or limited persistence. In human AUD, DemeRx is trying to position DMX-1001 not just as another craving-reduction agent, but as a candidate aimed at relapse risk, mood comorbidity, and underlying circuit dysfunction. Whether that framing holds up clinically is still an open question. (biospace.com)
For the addiction treatment field, the bigger issue is execution. IND acceptance is important, but it’s not proof of efficacy, and noribogaine-derived development will likely continue to face scrutiny around cardiac monitoring, abuse liability assumptions, and how well early healthy-volunteer data translate into a real-world AUD population with psychiatric and medical comorbidities. The company’s own timeline suggests the next meaningful inflection point is not immediate commercialization, but generation of alcohol interaction data and then Phase 2 initiation. (biospace.com)
What to watch: The next markers are the alcohol interaction trial, fuller disclosure of the IND-enabling package and protocol design, and confirmation that DemeRx can open a Phase 2 AUD study in 2027. If that happens, the field will get its first clearer read on whether the neuroplastogen thesis can translate from mechanistic promise into clinically meaningful outcomes. (biospace.com)